目的：观察桂枝茯苓胶囊对子宫内膜炎大鼠的治疗作用，探讨其作用机制。方法：复制大鼠子宫内膜炎模型，造模15天后，随机分为假手术组，模型组，桂枝茯苓胶囊低、中、高剂量组（0.5、1.0、2.0 g·kg-1）和妇科千金胶囊组（1.2 g·kg-1）。各治疗组灌胃给药28 天，观察大鼠子宫内膜的病理变化，测定大鼠血清单核细胞趋化蛋白1（MCP-1）、白细胞介素1β（IL-1β）、白细胞介素10（IL-10）含量，免疫组织化学法检测各组大鼠子宫组织转化生长因子-β1（TGF-β1）蛋白表达。结果：桂枝茯苓胶囊能明显改善子宫内膜炎大鼠子宫内膜病变程度，与假手术组相比，模型组大鼠血清IL-10 含量显著降低，MCP-1、IL-1茁含量明显升高，子宫组织中TGF-β1蛋白表达显著升高。经桂枝茯苓胶囊治疗后，与模型组比较，治疗组大鼠血清IL-10明显增高，MCP-1、IL-1β含量明显降低，子宫组织中TGF-β1蛋白表达显著降低。结论：桂枝茯苓胶囊对子宫内膜炎症具有治疗作用，作用机制可能与调节炎症细胞因子有关。

This study was aimed to observe the therapeutic effect onendometritis rat model by Gui -Zhi Fu -Ling (GZFL) capsuleand its mechanism. Endometritis rat model was replicated. After 15 days, rats were randomly divided into six groups, which were the sham operation group, model group, lowdosage (0.5 g·kg-1) of GZFL capsule group, middle dosage (1.0 g·kg-1) of GZFL capsule group, large dosage (2.0 g·kg-1) of GZFL capsule group, and Fu-Ke Qian-Jin (FKQJ) capsule (1.2 g·kg-1) group. After 28-day intragastric administration of medication, pathological changes of endometrium were observed. The contents of monocyte chemoattractant protein-1 (MCP-1), interleukin-1β(IL-1β), interleukin-10 (IL-10) were determined in blood serum.The expression of TGF-β1 in endometritis rats were measured by immunohistochemistry. The results showed that GZFL capsule canobviously alleviate the pathological damage of endometrium in rat model. In comparison with sham operation group, the serum IL-10 content in the model group was significantly decreased, contents of MCP-1and IL-1β were significantly elevated; the TGF-β1 protein expression was significantly elevatedin the uterus tissues. After the treatment of GZFL capsule, compared with the model group, the serum IL-10 was obviously elevated in the treatment group. The contents of MCP-1 and IL-1β were obviously decreased. The expression of TGF-β1 in the uterus tissues was obviously decreased. It was concluded that GZFL capsule had treatment effect on endometritis. The mechanism may be related to the regulation of inflammatory cytokines.

科学技术部国家重大新药创制（2013ZX09402203）：现代中药创新集群与数字制药技术平台，负责人：王振中。